Biotechnology News and Research

RSS

IFR, PBL to further develop Dynamic Gastric Model

The Dynamic Gastric Model, developed from years of research at the Institute of Food Research, has taken significant steps towards improving its commercial use by food and drug companies worldwide.

26 Feb 2013

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).

26 Feb 2013

Anemia medication recall could affect thousands of kidney-disease patients

The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.

26 Feb 2013

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a "super bug," says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.

26 Feb 2013

Glide Pharma announces completion of $21.4 million investment round

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.

26 Feb 2013

External qigong therapy can help control cocaine craving early in recovery

Cocaine is one of the most addictive drugs of abuse. Few effective treatments are available to help control cravings and withdrawal symptoms among individuals undergoing therapy to overcome cocaine abuse.

26 Feb 2013

Robert Wood Johnson Medical Group physicians appear on the Best Doctors in America List

Eighty-five physicians affiliated with The Robert Wood Johnson Medical Group, the faculty practice of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, appear on the Best Doctors in America List for 2013.

26 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Researchers identify new function for matriptase enzyme

Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique Étienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus.

24 Feb 2013

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Cardiovascular disease specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute affiliated with the University of South Florida announced they have enrolled their first patients into a clinical trial testing a novel gene therapy for the treatment of heart failure after ischemic injury. The therapy may promote the regeneration of heart tissue by encouraging the body to deploy more stem cells to the injury site.

22 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

IntegraGen, Lab21 collaborate to develop new microRNA assay for colorectal cancer

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

22 Feb 2013

Antibody delivery system launched that works even in presence of additives

...

22 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award.

21 Feb 2013

J Cell Mol Med, Microbial Biotechnology join Wiley Open Access publishing program

John Wiley & Sons, Inc., announced today that Journal of Cellular and Molecular Medicine and Microbial Biotechnology have joined the Wiley Open Access publishing program. All articles in these two journals are now open access and free to view, download and share.

20 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Oncolytics Biotech to commence underwritten public offering of common shares

Oncolytics Biotech Inc. announced today its intention, subject to market and other conditions, to commence an underwritten public offering of common shares. The number of common shares to be distributed and the price of each common share will be determined in the context of the market with final terms to be determined at the time of pricing.

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).

16 Feb 2013

Biotechnology News and Research

IFR, PBL to further develop Dynamic Gastric Model

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Anemia medication recall could affect thousands of kidney-disease patients

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

Glide Pharma announces completion of $21.4 million investment round

External qigong therapy can help control cocaine craving early in recovery

Robert Wood Johnson Medical Group physicians appear on the Best Doctors in America List

Circassia announces results from ToleroMune cat allergy phase II clinical study

Researchers identify new function for matriptase enzyme

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Blaze Bioscience completes $8.5 million Series A financing

IntegraGen, Lab21 collaborate to develop new microRNA assay for colorectal cancer

Antibody delivery system launched that works even in presence of additives

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

J Cell Mol Med, Microbial Biotechnology join Wiley Open Access publishing program

TIR-199 shows promise in fighting renal cancer

Oncolytics Biotech to commence underwritten public offering of common shares

BioCryst fourth quarter revenues decrease to $4.1 million

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News